You might want to fact check what you said. It was darolutamide that was approved for monotherapy (on June 5th). The point I was trying to make is that Nubeqa alone (as well as other androgen blockers) might provide advantages over prolonged ADT because it allows for increased T. And therefore less genetic pressure on mutation to castration resistance.